The Role of Hormones in Hidradenitis Suppurativa: A Systematic Review
Abstract
:1. Introduction
2. Methods
3. Results
3.1. HS Manifestation and Exacerbation
3.2. Sexual Hormones
References | Type of Source | Aim | Results | Conclusion |
---|---|---|---|---|
Harrison et al., 1985 [20] | case-control study (n = 13; all female) | Investigation of endocrine abnormality in HS |
| In HS, there could rather be a disturbance of the feedback signals of peripheral hormones. |
Mortimer et al., 1986 [17] | case-control study (n = 42; all female) | role of sexual hormones in HS |
| In female patients with follicular type of HS, androgens seem to play a role in the pathogenesis. |
Buimer et al., 2015 [15] | experimental im-munohisto-chemical study (n = 22; 16 female and 6 male) | AR and ER immunoreactivity in apocrine glands of HS |
| Expression of AR and ER in apocrine glands has no decisive role in the pathogenesis of HS. |
Gauntner 2019 [14] | experimental study (n = 17; gender unknown) | gene expression microarray analysis from skin biopsies in HS |
| HS lesions show increased androgen receptor (AR) transcriptional activity, activation of stem-cell-associated transcriptional pathways, and upregulation of Notch-associated genetic loci. |
Zouboulis et al., 2020 [16] | experimental study (n = 16; 8 female and 8 male) | Transcriptome analysis to investigate the role of the apocrine glands in HS |
| Androgen-controlled genes are up-regulated in women, and genes that influence fat metabolism are down-regulated in men. The apocrine glands are of secondary importance in HS pathogenesis. |
Yu et al., 2021 [13] | experimental immunohistochemical study (n = 10; 6 female and 4 male) | AR immunoreactivity in HS skin tunnels, epidermis, and infundibulum |
| Androgens are involved in HS. The segmental AR expression pattern of the skin tunnels in women may be related to a response to antiandrogenic therapy. |
3.3. Anti-Androgen Therapy
References | TYPE OF SOURCE | Dose | Results | Conclusion |
---|---|---|---|---|
Joseph et al., 2005 [25] | case series in adults (n = 7; 5 female and 2 male) | 5 mg/d as monotherapy |
| Finasteride is an effective therapeutic option in HS |
Randhawa et al., 2013 [28] | case series in children with HS (n = 3; all female) | 5 mg/d as monotherapy |
| Finasteride is a therapeutic option for children |
Mota et al., 2017 [26] | case series in children with HS (n = 5; 4 female and 1 male) | 1 to 5 mg/d as monotherapy |
| Use of finasteride in AI may be a treatment option in children |
Babbush et al., 2022 [27] | retrospective chart review of female patients (n = 20; all female) | 5 mg/d as monotherapy |
| Finasteride is a safe and effective alternative for female patients with HS |
References | Type of Source | Dose | Results | Conclusion |
---|---|---|---|---|
Lee et al., 2015 [5] | case series of 20 women (n = 20; all female) | 100 to 150 mg/d as monotherapy ± minocycline ± cyproterone acetate |
| Spironolactone should be considered as first-line treatment in women |
Golbari et al., 2019 [6] | single-center retrospective study (n = 67; all female) | 25 to 200 mg/d as monotherapy ± antibiotics ± contraceptives |
| Spironolactone reduces lesion count, HS-PGA score, and pain |
McPhie et al., 2019 [35] | retrospective chart review (n = 12; gender unknown) | 100 mg/d ± adalimumab ± isotretinoin or/and doxycycline |
| Combination therapy, e.g., with spironolactone, can be useful |
Quinlan et al., 2020 [37] | retrospective study (n = 26; all female) | monotherapy with 50 to 100 mg/d |
| Spironolactone appears to be a treatment option for women with HS |
Horissian et al., 2022 [32] | epidemiological cross-sectional analysis (n = 215; all female) | dose unknown |
| Increased use of spironolactone is likely driven by the successful treatment. |
References | Type of Source | Dose | Results | Conclusion |
---|---|---|---|---|
Sawers et al., 1986 [39] | case series (n = 4; all female) | CPA 100 mg/d + 30 to 50 µg/d ethinyl oestradio |
| In HS, there is an androgen-dependent disorder. Combined cyproterone acetate and estrogen therapy in women may be useful. |
Mortimer et al., 1986 [38] | randomized double-blind crossover trial (n = 24; all female) | CPA 50 mg/d + 50 µg/d ethinyl oestradio |
| Anti-androgen therapy may be beneficial in HS. |
Kraft et al., 2007 [23] | retrospective chart review (n = 29; all female) | CPA 2 to 25 mg/d + 35 µg/d ethinyl oestradio ± spironolactone 100 mg/d |
| Hormone treatment should be considered for women. |
3.4. Insulin Resistance and Adipokines
References | Type of Source | Aim | Results | Conclusion |
---|---|---|---|---|
Malara et al., 2018 [50] | case-control study (n = 30; gender unknown) compared to psoriasis, nondiabetic obese (BMI > 30), and lean control groups (BMI < 25) | analysis of adipokines (adiponectin, resistin, and leptin) in serum in HS |
| Serum levels of adipokines are dysregulated in HS and are associated with obesity. |
Vilanova et al., 2018 [60] | cross-sectional, case-control study (n = 76; 39 female and 37 male) | aim was to analyze the prevalence of insulin resistance (IR) in patients with HS |
| Increased frequency of IR in HS. |
Akdogan et al., 2018 [51] | case-control study (n = 40; 17 female and 23 male) | aim was to evaluate serum visfatin levels (SVLs), insulin levels (SILs), and insulin resistance (IR) in HS |
| HS patients have higher SVL, SIL, and IR values than healthy controls—independent of BMI and smoking status. |
González-López et al., 2020 [52] | case-control study (n = 76; 40 female and 36 male) | aim was to analyze serum concentrations of adiponectin, leptin, resistin, and visfatin in non-diabetic patients with HS |
| Adipokines might play a role in development of insulin resistance. |
González-López et al., 2020 [57] | cross-sectional, case-control study (n = 77; 40 female and 37 male) | aim was to determine the serum levels of Retinol binding protein 4 (RBP4) and ghrelin in HS, and to assess the relationship between these levels and IR, disease severity, and HS risk |
| High RBP4 levels may be a surrogate biomarker for IR in patients with HS.Increased RBP4 and decreased ghrelin levels could also be independent risk factors for development of HS. |
Özkur et al., 2020 [42] | case-control study (n = 37; 28 female and 9 male) | aim was to evaluate serum irisin, plasma glucose, insulin, and lipid levels in HS |
| Patients with HS should be screened for insulin resistance and metabolic syndrome. |
González-López et al., 2021 [58] | case-control study (n = 78; 41 female and 37 male) | aim was to investigate serum omentin-1 and apelin levels in non-diabetic patients with HS |
| Patients with HS have raised omentin-1 serum levels. |
References | Type of Source | Drug (Dose) | Results | Conclusion |
---|---|---|---|---|
Verdolini et al., 2013 [64] | prospective study (n = 25; 22 female and 3 male) | Metformin (dose of 500 to 1500 mg) |
| Metformin may be a therapeutic option for treatment of HS. |
Jennings et al., 2017 [67] | case report (n = 1; female) | Liraglutide (start with 0.6 mg subcutaneously per day, then weekly 1.8 mg) |
| In obese patients with HS, use of liraglutide may be beneficial. |
Moussa et al., 2020 [65] | retrospective chart review with pediatric patients (n = 16; gender unknown) | Metformin (dose unknown) |
| Metformin as add-on therapy can lead to better control of HS in children, with minimal side effects. |
Jennings et al., 2020 [66] | retrospective chart review (n = 53; 45 female and 8 male) | Metformin (dose of 500 to 1500 mg) |
| Metformin is an effective, well-tolerated, and cost-effective treatment for HS. |
3.5. Thyroid Function in HS
3.6. Polycystic Ovary Syndrome (PCOS) and HS
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Jfri, A.; Nassim, D.; O’Brien, E.; Gulliver, W.; Nikolakis, G.; Zouboulis, C.C. Prevalence of Hidradenitis Suppurativa: A Systematic Review and Meta-regression Analysis. JAMA Dermatol. 2021, 157, 924–931. [Google Scholar] [CrossRef]
- Ingram, J.R.; Collins, H.; Atkinson, M.D.; Brooks, C.J. The prevalence of hidradenitis suppurativa is shown by the Secure Anonymised Information Linkage (SAIL) Databank to be one per cent of the population of Wales. Br. J. Dermatol. 2020, 183, 950–952. [Google Scholar] [CrossRef] [PubMed]
- Jemec, G.B.; Heidenheim, M.; Nielsen, N.H. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J. Am. Acad. Dermatol. 1996, 35, 191–194. [Google Scholar] [CrossRef] [PubMed]
- Zouboulis, C.C.; Bechara, F.G.; Fritz, K.; Kurzen, H.; Liakou, A.I.; Marsch, W.C.; Milling, A.; Nast, A.; Podda, M.; Taube, K.M.; et al. S1-Leitlinie zur Therapie der Hidradenitis suppurativa/Acne inversa* (ICD-10 Ziffer: L73.2). J. Dtsch. Dermatol. Ges. 2012, 10 (Suppl. S5), S1–S31. [Google Scholar] [CrossRef] [PubMed]
- Lee, A.; Fischer, G. A case series of 20 women with hidradenitis suppurativa treated with spironolactone. Australas. J. Dermatol. 2015, 56, 192–196. [Google Scholar] [CrossRef]
- Golbari, N.M.; Porter, M.L.; Kimball, A.B. Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa. J. Am. Acad. Dermatol. 2019, 80, 114–119. [Google Scholar] [CrossRef]
- Fernandez, J.M.; Hendricks, A.J.; Thompson, A.M.; Mata, E.M.; Collier, E.K.; Grogan, T.R.; Shi, V.Y.; Hsiao, J.L. Menses, pregnancy, delivery, and menopause in hidradenitis suppurativa: A patient survey. Int. J. Women’s Dermatol. 2020, 6, 368–371. [Google Scholar] [CrossRef]
- Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann. Intern. Med. 2009, 151, 264–269. [Google Scholar] [CrossRef] [Green Version]
- Finlay, A.Y.; Khan, G.K. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 1994, 19, 210–216. [Google Scholar] [CrossRef]
- Zouboulis, C.C.; Tzellos, T.; Kyrgidis, A.; Jemec, G.B.E.; Bechara, F.G.; Giamarellos-Bourboulis, E.J.; Ingram, J.R.; Kanni, T.; Karagiannidis, I.; Martorell, A.; et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol 2017, 177, 1401–1409. [Google Scholar] [CrossRef]
- Vossen, A.R.J.V.; van Straalen, K.R.; Prens, E.P.; van der Zee, H.H. Menses and pregnancy affect symptoms in hidradenitis suppurativa: A cross-sectional study. J. Am. Acad. Dermatol. 2017, 76, 155–156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seivright, J.R.; Villa, N.M.; Grogan, T.; Parvataneni, R.K.; Thompson, A.M.; Shi, V.Y.; Hsiao, J.L. Impact of Pregnancy on Hidradenitis Suppurativa Disease Course: A Systematic Review and Meta-Analysis. Dermatology 2022, 238, 260–266. [Google Scholar] [CrossRef] [PubMed]
- Yu, W.; Barrett, J.; Liu, P.; Parameswaran, A.; Chiu, E.S.; Lu, C.P. Novel evidence of androgen receptor immunoreactivity in skin tunnels of hidradenitis suppurativa: Assessment of sex and individual variability. Br J Dermatol 2021, 185, 855–858. [Google Scholar] [CrossRef] [PubMed]
- Gauntner, T.D. Hormonal, stem cell and Notch signalling as possible mechanisms of disease in hidradenitis suppurativa: A systems-level transcriptomic analysis. Br J Dermatol 2019, 180, 203–204. [Google Scholar] [CrossRef] [Green Version]
- Buimer, M.G.; Wobbes, T.; Klinkenbijl, J.H.G.; Reijnen, M.M.P.J.; Blokx, W.A.M. Immunohistochemical analysis of steroid hormone receptors in hidradenitis suppurativa. Am. J. Dermatopathol. 2015, 37, 129–132. [Google Scholar] [CrossRef]
- Zouboulis, C.C.; Da Nogueira Costa, A.; Fimmel, S.; Zouboulis, K.C. Apocrine glands are bystanders in hidradenitis suppurativa and their involvement is gender specific. J. Eur. Acad. Dermatol. Venereol. 2020, 34, 1555–1563. [Google Scholar] [CrossRef] [Green Version]
- Mortimer, P.S.; Dawber, R.P.; Gales, M.A.; Moore, R.A. Mediation of hidradenitis suppurativa by androgens. Br. Med. J. (Clin Res. Ed) 1986, 292, 245–248. [Google Scholar] [CrossRef] [Green Version]
- Buonomo, M.; Mansh, M.D.; Thorpe, D.; Goldfarb, N. Development or exacerbation of hidradenitis suppurativa in two transgender men after initiation of testosterone therapy. Br. J. Dermatol. 2021, 184, 1192–1194. [Google Scholar] [CrossRef]
- Ramos-Rodríguez, D.; Garcias-Ladaria, J.; Serra Soler, G.; Martín-Santiago, A. Hidradenitis suppurativa in a transgender man. Clin. Exp. Dermatol. 2021, 46, 1305–1306. [Google Scholar] [CrossRef]
- Harrison, B.J.; Kumar, S.; Read, G.F.; Edwards, C.A.; Scanlon, M.F.; Hughes, L.E. Hidradenitis suppurativa: Evidence for an endocrine abnormality. Br. J. Surg. 1985, 72, 1002–1004. [Google Scholar] [CrossRef]
- Targum, S.D.; Marshall, L.E.; Magac-Harris, K.; Martin, D. TRH tests in a healthy elderly population. Demonstration of gender differences. J. Am. Geriatr. Soc. 1989, 37, 533–536. [Google Scholar] [CrossRef] [PubMed]
- Dysken, M.W.; Falk, A.; Pew, B.; Kuskowski, M.; Krahn, D.D. Gender differences in TRH-stimulated TSH and prolactin in primary degenerative dementia and elderly controls. Biological Psychiatry 1990, 28, 144–150. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kraft, J.N.; Searles, G.E. Hidradenitis suppurativa in 64 female patients: Retrospective study comparing oral antibiotics and antiandrogen therapy. J. Cutan. Med. Surg. 2007, 11, 125–131. [Google Scholar] [CrossRef] [PubMed]
- Alikhan, A.; Sayed, C.; Alavi, A.; Alhusayen, R.; Brassard, A.; Burkhart, C.; Crowell, K.; Eisen, D.B.; Gottlieb, A.B.; Hamzavi, I.; et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J. Am. Acad. Dermatol. 2019, 81, 91–101. [Google Scholar] [CrossRef] [Green Version]
- Joseph, M.A.; Jayaseelan, E.; Ganapathi, B.; Stephen, J. Hidradenitis suppurativa treated with finasteride. J. Dermatolog. Treat. 2005, 16, 75–78. [Google Scholar] [CrossRef]
- Mota, F.; Machado, S.; Selores, M. Hidradenitis Suppurativa in Children Treated with Finasteride-A Case Series. Pediatr. Dermatol. 2017, 34, 578–583. [Google Scholar] [CrossRef]
- Babbush, K.M.; Andriano, T.M.; Cohen, S.R. Antiandrogen therapy in hidradenitis suppurativa: Finasteride for females. Clin. Exp. Dermatol. 2022, 47, 86–92. [Google Scholar] [CrossRef]
- Randhawa, H.K.; Hamilton, J.; Pope, E. Finasteride for the treatment of hidradenitis suppurativa in children and adolescents. JAMA Dermatol. 2013, 149, 732–735. [Google Scholar] [CrossRef] [Green Version]
- Naamneh Elzenaty, R.; Du Toit, T.; Flück, C.E. Basics of androgen synthesis and action. Best Pract. Res. Clin. Endocrinol. Metab. 2022, 36, 101665. [Google Scholar] [CrossRef] [PubMed]
- Salisbury, B.H.; Tadi, P. StatPearls: 5 Alpha Reductase Inhibitors; StatPearls Publishing: St. Petersburg, FL, USA, 2022. [Google Scholar]
- Abdelmaksoud, A. Comment on “Hidradenitis suppurativa in children treated with finasteride-A case series”. Pediatr. Dermatol. 2018, 35, 158. [Google Scholar] [CrossRef]
- Horissian, M.; Maczuga, S.; Barbieri, J.S.; Zaenglein, A.L. Trends in the prescribing pattern of spironolactone for acne and hidradenitis suppurativa in adolescents. J. Am. Acad. Dermatol. 2022, 87, 684–686. [Google Scholar] [CrossRef] [PubMed]
- Barbieri, J.S.; James, W.D.; Margolis, D.J. Trends in prescribing behavior of systemic agents used in the treatment of acne among dermatologists and nondermatologists: A retrospective analysis, 2004-2013. J. Am. Acad. Dermatol. 2017, 77, 456–463.e4. [Google Scholar] [CrossRef]
- Patibandla, S.; Heaton, J.; Kyaw, H. StatPearls: Spironolactone; StatPearls Publishing: St. Petersburg, FL, USA, 2022. [Google Scholar]
- McPhie, M.L.; Bridgman, A.C.; Kirchhof, M.G. Combination Therapies for Hidradenitis Suppurativa: A Retrospective Chart Review of 31 Patients. J. Cutan. Med. Surg. 2019, 23, 270–276. [Google Scholar] [CrossRef]
- Miller, I.M.; Vinding, G.; Sørensen, H.A.; Rytgaard, H.; Mogensen, U.B.; Ellervik, C.; Jemec, G.B. Thyroid function in hidradenitis suppurativa: A population-based cross-sectional study from Denmark. Clin. Exp. Dermatol. 2018, 43, 899–905. [Google Scholar] [CrossRef] [PubMed]
- Quinlan, C.; Kirby, B.; Hughes, R. Spironolactone therapy for hidradenitis suppurativa. Clin. Exp. Dermatol. 2020, 45, 464–465. [Google Scholar] [CrossRef] [PubMed]
- Mortimer, P.S.; Dawber, R.P.; Gales, M.A.; Moore, R.A. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br. J. Dermatol. 1986, 115, 263–268. [Google Scholar] [CrossRef]
- Sawers, R.S.; Randall, V.A.; Ebling, F.J. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy. Br J Dermatol 1986, 115, 269–274. [Google Scholar] [CrossRef]
- Li, C.; Xu, H.; Zhang, X.; Zhang, W.; He, Y.; Wang, B. Hidradenitis suppurativa is treated with low-dose flutamide. J. Dermatol. 2019, 46, e52–e54. [Google Scholar] [CrossRef] [PubMed]
- Sabat, R.; Chanwangpong, A.; Schneider-Burrus, S.; Metternich, D.; Kokolakis, G.; Kurek, A.; Philipp, S.; Uribe, D.; Wolk, K.; Sterry, W. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS ONE 2012, 7, e31810. [Google Scholar] [CrossRef]
- Özkur, E.; Erdem, Y.; Altunay, İ.K.; Demir, D.; Dolu, N.Ç.; Serin, E.; Çerman, A.A. Serum irisin level, insulin resistance, and lipid profiles in patients with hidradenitis suppurativa: A case-control study. An. Bras. Dermatol. 2020, 95, 708–713. [Google Scholar] [CrossRef]
- Mintoff, D.; Benhadou, F.; Pace, N.P.; Frew, J.W. Metabolic syndrome and hidradenitis suppurativa: Epidemiological, molecular, and therapeutic aspects. Int. J. Dermatol. 2022, 61, 1175–1186. [Google Scholar] [CrossRef] [PubMed]
- Shlyankevich, J.; Chen, A.J.; Kim, G.E.; Kimball, A.B. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: A chart-verified case-control analysis. J. Am. Acad. Dermatol. 2014, 71, 1144–1150. [Google Scholar] [CrossRef] [PubMed]
- Lee, J.H.; Kwon, H.S.; Jung, H.M.; Kim, G.M.; Bae, J.M. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: A nationwide population-based study. J. Eur. Acad. Dermatol. Venereol. 2018, 32, 1784–1790. [Google Scholar] [CrossRef] [PubMed]
- Phan, K.; Charlton, O.; Smith, S.D. Hidradenitis suppurativa and diabetes mellitus: Updated systematic review and adjusted meta-analysis. Clin. Exp. Dermatol. 2019, 44, e126–e132. [Google Scholar] [CrossRef]
- Garg, A.; Birabaharan, M.; Strunk, A. Prevalence of type 2 diabetes mellitus among patients with hidradenitis suppurativa in the United States. J. Am. Acad. Dermatol. 2018, 79, 71–76. [Google Scholar] [CrossRef]
- Shalom, G.; Freud, T.; Harman-Boehm, I.; Polishchuk, I.; Cohen, A.D. Hidradenitis suppurativa and metabolic syndrome: A comparative cross-sectional study of 3207 patients. Br. J. Dermatol. 2015, 173, 464–470. [Google Scholar] [CrossRef]
- Nakamura, K.; Fuster, J.J.; Walsh, K. Adipokines: A link between obesity and cardiovascular disease. J. Cardiol. 2014, 63, 250–259. [Google Scholar] [CrossRef] [Green Version]
- Malara, A.; Hughes, R.; Jennings, L.; Sweeney, C.M.; Lynch, M.; Awdeh, F.; Timoney, I.; Tobin, A.M.; Lynam-Loane, K.; Tobin, L.; et al. Adipokines are dysregulated in patients with hidradenitis suppurativa. Br. J. Dermatol. 2018, 178, 792–793. [Google Scholar] [CrossRef]
- Akdogan, N.; Alli, N.; Uysal, P.I.; Topcuoglu, C.; Candar, T.; Turhan, T. Visfatin and insulin levels and cigarette smoking are independent risk factors for hidradenitis suppurativa: A case-control study. Archives of dermatological research 2018, 310, 785–793. [Google Scholar] [CrossRef]
- González-López, M.A.; Vilanova, I.; Ocejo-Viñals, G.; Arlegui, R.; Navarro, I.; Guiral, S.; Mata, C.; Pérez-Paredes, M.G.; Portilla, V.; Corrales, A.; et al. Circulating levels of adiponectin, leptin, resistin and visfatin in non-diabetics patients with hidradenitis suppurativa. Archives of dermatological research 2020, 312, 595–600. [Google Scholar] [CrossRef]
- Frances, L.; Tavernier, G.; Viguerie, N. Adipose-Derived Lipid-Binding Proteins: The Good, the Bad and the Metabolic Diseases. Int. J. Mol. Sci. 2021, 22, 460. [Google Scholar] [CrossRef] [PubMed]
- Lee, D.-C.; Lee, J.-W.; Im, J.-A. Association of serum retinol binding protein 4 and insulin resistance in apparently healthy adolescents. Metabolism 2007, 56, 327–331. [Google Scholar] [CrossRef]
- Cho, Y.M.; Youn, B.-S.; Lee, H.; Lee, N.; Min, S.-S.; Kwak, S.H.; Lee, H.K.; Park, K.S. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006, 29, 2457–2461. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kelly, M.; Widjaja-Adhi, M.A.K.; Palczewski, G.; Lintig, J. von. Transport of vitamin A across blood-tissue barriers is facilitated by STRA6. FASEB J. 2016, 30, 2985–2995. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- González-López, M.A.; Ocejo-Viñals, J.G.; Mata, C.; Vilanova, I.; Guiral, S.; Portilla, V.; Blanco, R.; Hernández, J.L. Association of retinol binding protein4 (RBP4) and ghrelin plasma levels with insulin resistance and disease severity in non-diabetic patients with hidradenitis suppurativa. Exp. Dermatol. 2020, 29, 828–832. [Google Scholar] [CrossRef] [PubMed]
- González-López, M.A.; Ocejo-Viñals, J.G.; Mata, C.; Díaz, D.; Guiral, S.; Portilla, V.; Corrales, A.; González-Vela, M.C.; González-Gay, M.A.; Blanco, R.; et al. Evaluation of serum omentin-1 and apelin concentrations in patients with hidradenitis suppurativa. Postepy Dermatol. Alergol. 2021, 38, 450–454. [Google Scholar] [CrossRef]
- Watanabe, T.; Watanabe-Kominato, K.; Takahashi, Y.; Kojima, M.; Watanabe, R. Adipose Tissue-Derived Omentin-1 Function and Regulation. Compr. Physiol. 2017, 7, 765–781. [Google Scholar] [CrossRef] [PubMed]
- Vilanova, I.; Hernández, J.L.; Mata, C.; Durán, C.; García-Unzueta, M.T.; Portilla, V.; Fuentevilla, P.; Corrales, A.; González-Vela, M.C.; González-Gay, M.A.; et al. Insulin resistance in hidradenitis suppurativa: A case-control study. J. Eur. Acad. Dermatol. Venereol. 2018, 32, 820–824. [Google Scholar] [CrossRef] [Green Version]
- Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28, 412–419. [Google Scholar] [CrossRef] [Green Version]
- Macklis, P.C.; Tyler, K.; Kaffenberger, J.; Kwatra, S.; Kaffenberger, B.H. Lifestyle modifications associated with symptom improvement in hidradenitis suppurativa patients. Arch. Dermatol. Res. 2022, 314, 293–300. [Google Scholar] [CrossRef]
- Chung, M.-M.; Nicol, C.J.; Cheng, Y.-C.; Lin, K.-H.; Chen, Y.-L.; Pei, D.; Lin, C.-H.; Shih, Y.-N.; Yen, C.-H.; Chen, S.-J.; et al. Metformin activation of AMPK suppresses AGE-induced inflammatory response in hNSCs. Exp. Cell Res. 2017, 352, 75–83. [Google Scholar] [CrossRef] [PubMed]
- Verdolini, R.; Clayton, N.; Smith, A.; Alwash, N.; Mannello, B. Metformin for the treatment of hidradenitis suppurativa: A little help along the way. J. Eur. Acad. Dermatol. Venereol. 2013, 27, 1101–1108. [Google Scholar] [CrossRef] [PubMed]
- Moussa, C.; Wadowski, L.; Price, H.; Mirea, L.; O’Haver, J. Metformin as Adjunctive Therapy for Pediatric Patients With Hidradenitis Suppurativa. J. Drugs Dermatol. 2020, 19, 1231–1234. [Google Scholar] [CrossRef]
- Jennings, L.; Hambly, R.; Hughes, R.; Moriarty, B.; Kirby, B. Metformin use in hidradenitis suppurativa. J. Dermatolog. Treat. 2020, 31, 261–263. [Google Scholar] [CrossRef] [PubMed]
- Jennings, L.; Nestor, L.; Molloy, O.; Hughes, R.; Moriarty, B.; Kirby, B. The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide. Br. J. Dermatol. 2017, 177, 858–859. [Google Scholar] [CrossRef]
- Emtestam, L.; Sartorius, K. Glucagon-like peptide-1 agonists for treatment of hidradenitis suppurativa. Br. J. Dermatol. 2017, 177, 625–627. [Google Scholar] [CrossRef]
- Müller, P.; Leow, M.K.-S.; Dietrich, J.W. Minor perturbations of thyroid homeostasis and major cardiovascular endpoints-Physiological mechanisms and clinical evidence. Front. Cardiovasc. Med. 2022, 9, 942971. [Google Scholar] [CrossRef]
- Kimball, A.B.; Sundaram, M.; Gauthier, G.; Guérin, A.; Pivneva, I.; Singh, R.; Ganguli, A. The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data Analysis. Dermatol. Ther. (Heidelb) 2018, 8, 557–569. [Google Scholar] [CrossRef] [Green Version]
- Liakou, A.I.; Kontochristopoulos, G.; Marnelakis, I.; Tsantes, A.G.; Papadakis, M.; Alevizou, A.; Rotsiamis, N.; Rigopoulos, D. Thyroid Disease and Active Smoking May Be Associated with More Severe Hidradenitis Suppurativa: Data from a Prospective Cross Sectional Single-Center Study. Dermatology 2021, 237, 125–130. [Google Scholar] [CrossRef]
- Sherman, S.; Tzur Bitan, D.; Kridin, K.; Pavlovsky, L.; Hodak, E.; Cohen, A.D. Hidradenitis suppurativa is associated with hypothyroidism and hyperthyroidism: A large-scale population-based study. Int. J. Dermatol. 2021, 60, 321–326. [Google Scholar] [CrossRef]
- López-Llunell, C.; Romaní, J.; Garbayo-Salmons, P.; Agut-Busquet, E. Vulvar hidradenitis suppurativa: Clinical cross-sectional study of 25 patients. J. Dermatol. 2021, 48, 457–463. [Google Scholar] [CrossRef] [PubMed]
- Andersen, R.K.; Loft, I.C.; Burgdorf, K.; Erikstrup, C.; Pedersen, O.B.; Jemec, G.B.E. Risk of Hidradenitis Suppurativa Comorbidities Over Time: A Prospective Cohort Study of Danish Blood Donors. Acta Derm. Venereol. 2021, 101, adv00376. [Google Scholar] [CrossRef] [PubMed]
- González-López, M.A.; Hernández, J.L.; Vilanova, I.; Mata, C.; López-Escobar, M.; González-Vela, M.C.; López-Hoyos, M.; González-Gay, M.A.; Blanco, R. Thyroid autoimmunity in patients with hidradenitis suppurativa: A case-control study. Clin. Exp. Dermatol. 2017, 42, 642–644. [Google Scholar] [CrossRef] [PubMed]
- Phan, K.; Charlton, O.; Smith, S.D. Hidradenitis suppurativa and polycystic ovarian syndrome: Systematic review and meta-analysis. Australas. J. Dermatol. 2020, 61, e28–e33. [Google Scholar] [CrossRef] [PubMed]
- Garg, A.; Neuren, E.; Strunk, A. Hidradenitis Suppurativa Is Associated with Polycystic Ovary Syndrome: A Population-Based Analysis in the United States. J. Invest. Dermatol. 2018, 138, 1288–1292. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Canoui-Poitrine, F.; Le Thuaut, A.; Revuz, J.E.; Viallette, C.; Gabison, G.; Poli, F.; Pouget, F.; Wolkenstein, P.; Bastuji-Garin, S. Identification of three hidradenitis suppurativa phenotypes: Latent class analysis of a cross-sectional study. J. Invest. Dermatol. 2013, 133, 1506–1511. [Google Scholar] [CrossRef] [Green Version]
- Tzellos, T.; Zouboulis, C.C.; Gulliver, W.; Cohen, A.D.; Wolkenstein, P.; Jemec, G.B.E. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: A systematic review and meta-analysis of observational studies. Br J Dermatol 2015, 173, 1142–1155. [Google Scholar] [CrossRef]
- Gambichler, T.; Hessam, S.; Cramer, P.; Abu Rached, N.; Bechara, F.G. Complete blood collection-based systemic inflammation biomarkers for patients with hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 2022, 36, 1593–1596. [Google Scholar] [CrossRef]
- Sivanand, A.; Gulliver, W.P.; Josan, C.K.; Alhusayen, R.; Fleming, P.J. Weight Loss and Dietary Interventions for Hidradenitis Suppurativa: A Systematic Review. J. Cutan. Med. Surg. 2020, 24, 64–72. [Google Scholar] [CrossRef] [PubMed]
- Damiani, G.; Mahroum, N.; Pigatto, P.D.M.; Pacifico, A.; Malagoli, P.; Tiodorovic, D.; Conic, R.R.; Amital, H.; Bragazzi, N.L.; Watad, A.; et al. The Safety and Impact of a Model of Intermittent, Time-Restricted Circadian Fasting (“Ramadan Fasting”) on Hidradenitis Suppurativa: Insights from a Multicenter, Observational, Cross-Over, Pilot, Exploratory Study. Nutrients 2019, 11, 1781. [Google Scholar] [CrossRef] [PubMed]
- Prasetya, G.; Sapwarobol, S. Intermittent Fasting During Ramadan Improves Insulin Sensitivity and Anthropometric Parameters in Healthy Young Muslim Men. Am. J. Lifestyle Med. 2021, 15, 200–206. [Google Scholar] [CrossRef] [PubMed]
- Gnanou, J.V.; Caszo, B.A.; Khalil, K.M.; Abdullah, S.L.; Knight, V.F.; Bidin, M.Z. Effects of Ramadan fasting on glucose homeostasis and adiponectin levels in healthy adult males. J. Diabetes Metab. Disord. 2015, 14, 55. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gaeini, Z.; Mirmiran, P.; Bahadoran, Z. Effects of Ramadan intermittent fasting on leptin and adiponectin: A systematic review and meta-analysis. Hormones (Athens) 2021, 20, 237–246. [Google Scholar] [CrossRef] [PubMed]
- Dilworth, L.; Facey, A.; Omoruyi, F. Diabetes Mellitus and Its Metabolic Complications: The Role of Adipose Tissues. Int. J. Mol. Sci. 2021, 22, 7644. [Google Scholar] [CrossRef]
References | Type of Source | Menses | During Pregnancy | Postmenopausal | Conclusion |
---|---|---|---|---|---|
Vossen et al., 2017 [11] | survey-based cross-sectional study (n = 186; all female) | worsening around menses (43%); no change (53.8%) | worsening (16.7%); no change (53.1%); improvement (30.2%) | no data | There is a significant correlation between perimenstrual worsening and improvement during pregnancy (p < 0.01). |
Fernandez et al., 2020 [7] | survey in an international HS group (n = 279; all female) | worsening of HS (76.7%); no change (22.2%); improvement (1.1%) | worsening (34.8%); no change (28.7%); improvement (36.6%) | worsening (39.5%); no change (44.2%); improvement (16.6%) | Menstruation causes exacerbation of HS. Pregnancy has mixed effects on HS. |
Seivright et al., 2022 [12] | Meta-analyses with 8 studies (n = 672; all female) | no data | worsening (20%); no change (56%); improvement (24%) postpartum deterioration: 60% of patients | no data | During pregnancy, the disease is stable in most cases. After birth, HS worsens in 60% of patients. |
References | Type of Source | Results | Conclusion |
---|---|---|---|
Shlyankevich et al., 2014 [44] | retrospective case-control study (n = 1776; 1296 female and 480 male) |
| HS is associated with thyroid disease. |
Gonzoalez-Lopez et al., 2017 [75] | case control study (n = 70; 38 female and 32 male) |
| Autoimmunity of the thyroid gland is not involved in development of HS. |
Lee et al., 2018 [45] | case-control study (n = 28,516; 11,036 female and 17,480 male) |
| Autoimmunity of the thyroid gland is not involved in development of HS. |
Miller et al., 2018 [36] | retrospective comparative cross-sectional study (n = 430; 292 female and 138 male) |
| HS is associated with hyperthyroidism. |
Kimball et al., 2018 [70] | retrospective matched cohort design (n = 5357; 3873 female and 1484 male) |
| HS is associated with thyroid disease.Autoimmunity of the thyroid gland is not involved in development of HS. |
Sherman et al., 2021 [72] | cross-sectional large-scale population-based study (n = 4191; 2590 female and 1601 male) |
| HS is independently associated with hypothyroidism. |
Liakou et al., 2021 [71] | prospective cross-sectional single-center study (n = 290; 248 female and 242 male) |
| Thyroid disorders and active smoking are significantly associated with a higher HS stage. |
López-Llunell et al., 2021 [73] | clinical cross-sectional study (n = 25; all female) |
| VHS is significantly associated with later onset, lower BMI, and thyroid disease. |
Andersen et al., 2021 [74] | prospective survival analysis on a nationwide cohort of blood donors (n = 40; 23 female and 17 male) |
| Comorbidities (e.g., diabetes, thyroid disease) may occur first in severe disease or later in the course of the disease. |
References | Type of Source | Results | Conclusion |
---|---|---|---|
Garg et al., 2018 [77] | case-control study (n = 2090; all female) |
| HS is associated with PCOS. |
Phan et al., 2020 [76] | Meta-analyses with 5 case-control studies (n = 20,532; all female) |
| There is a link between HS and PCOS. HS patients with evidence of hyperandrogenism may benefit from screening for PCOS and from antiandrogen therapy. |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Abu Rached, N.; Gambichler, T.; Dietrich, J.W.; Ocker, L.; Seifert, C.; Stockfleth, E.; Bechara, F.G. The Role of Hormones in Hidradenitis Suppurativa: A Systematic Review. Int. J. Mol. Sci. 2022, 23, 15250. https://doi.org/10.3390/ijms232315250
Abu Rached N, Gambichler T, Dietrich JW, Ocker L, Seifert C, Stockfleth E, Bechara FG. The Role of Hormones in Hidradenitis Suppurativa: A Systematic Review. International Journal of Molecular Sciences. 2022; 23(23):15250. https://doi.org/10.3390/ijms232315250
Chicago/Turabian StyleAbu Rached, Nessr, Thilo Gambichler, Johannes W. Dietrich, Lennart Ocker, Caroline Seifert, Eggert Stockfleth, and Falk G. Bechara. 2022. "The Role of Hormones in Hidradenitis Suppurativa: A Systematic Review" International Journal of Molecular Sciences 23, no. 23: 15250. https://doi.org/10.3390/ijms232315250